Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca AB
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Multiple Doses of Esomeprazole Magnesium in a Pediatric Population of 1 to 11 Year olds with Gastroesophageal Reflux Disease (GERD) or Symptoms of GERD
Primary Objective: To determine the area under the curve (AUC) of esomeprazole after multiple oral doses of 5 mg, 10 mg, and 20 mg esomeprazole magnesium in 1 to 11 year olds, inclusive with GERD or ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Phase I/II Study of AZD2014 given in combination with palbociclib on a background of fulvestrant for treatment of advanced ER + breast cancer that is locally advanced or has spread to other parts of the body
PARTS A, B1, B2: To investigate the safety and tolerability of the triplet combination (AZD2014 and palbociclib on a background of fulvestrant) in the patient groups. PART B3: To investigate the i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
The "EXTEND" study: A randomized, double-blind, parallel-group, phase IIIb, multi-centre study evaluating extended prophylactic treatment with melagatran/ximelagatran versus enoxaparin for the prevention of venous thromboembolic events in patients undergoing elective hip replacement or hip fracture surgery
See Clinical Study Protocol.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease
To evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients with Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy with a Statin
The two primary objectives of this study are to assess whether tesaglitazar is superior to metformin and non-inferior to metformin combined with fenofibrate in increasing high density lipoprotein-chol...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung Cancer
To assess the efficacy of MEDI4736 treatment compared with placebo in terms of OS and PFS
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A study to evaluate the efficacy and safety of dapagliflozin and dapagliflozin in combination with saxagliptin in type 2 diabetes with kidney disease. Ensayo para evaluar el efecto y la seguridad de dapaglifozina y dapaglifozina en combinación con saxagiptina en pacientes con diabetes tipo 2 con enfermedad renal crónica
Primary objectives for the Saxagliptin/Dapagliflozin treatment arm - To compare the mean change from baseline in HbA1c between dapagliflozin 10 mg plus saxagliptin 2.5 mg and placebo, after 24 weeks o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB, European Regulatory Affairs
MAJ Il y a 4 ans
A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenoulsy for Cardioversion of Atrial Fibrillation
Primary safety objective: To evaluate the dose-response relationship for QT effects of AZD1305 Primary efficacy objective: To demonstrate a dose-response relationship for AZD1305 given intravenously f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Phase III, Randomised, Double-Blind, Multi-Centre Parallel-Group Study to Assess the Efficacy of ZD6474 (ZACTIMA™ ) Versus Erlotinib (TARCEVA®) in Patients With Locally Advanced or Metastatic (Stage IIIB – IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of at least One Prior Cytotoxic Chemotherapy
The primary objective of this study is to demonstrate an improvement in Progression Free Survival (PFS) for ZD6474 (ZACTIMA™ ) Versus Erlotinib (Tarceva®) in patients with locally advanced or metastat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A randomized, double-blind, placebo controlled, three-way crossover study exploring the efficacy of AZD3778 compared with placebo and an oral antihistamine (loratadine) in a model of seasonal allergic rhinitis
The primary objective of this study is to explore the efficacy of AZD3778 compared with placebo and an oral antihistamine, Loratadine, in relieving the symptoms of allergic rhinitis in a model of seas...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
12
13
14
15
16
17
18
19
20
21
Suivant